To continue using this website, please tell us a
little about yourself:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies on the website and how to delete cookies, see our Privacy and Cookie Policy.

I accept the FE Trustnet cookie policy

For more information Click here



It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table

The Biotech Growth Trust PLC

Change Share Class?

The Biotech Growth Trust PLC
  • This fund only has one share class
Select Performance Currency
Pound Sterling
  • What is the Fund’s objective?

    The Biotech Growth Trust PLC seeks capital appreciation through investment in the worldwide biotechnology industry. Performance is measured against its benchmark index, the NASDAQ Biotechnology Index (sterling adjusted).

    How does FE rate this fund?

    • No FE Alpha managers
    • 2
    • Not included in the AFI

    Who manages this fund?

    Orbimed Capital Since 23-Jun-1997

    Manager biography not available


    Geoffrey C. Hsu Since 19-May-2005

    Geoffrey C. Hsu, CFA, is a General Partner of OrbiMed, having joined in 2002 as a public biotechnology analyst. Prior...


    Richard D Klemm Since 19-May-2005

    Richard D. Klemm, Ph.D., CFA, joined OrbiMed in 2000 as a public biotechnology company analyst. He completed a Ph.D....


  • How has this fund performed?

    Cumulative Performance chart

    Cumulative Performance as at 19/10/2017
        3m 6m 1yr 3yrs 5yrs
    The Biotech Growth Trust PLC +7.1 +21.5 +25.2 +61.9 +190.0
    Biotechnology & Healthcare +3.6 +12.0 +19.3 +76.9 +172.8
    NAV +4.8 +18.9 +22.7 +59.4 +208.5

    Discrete Performance chart

  • Forensic News Alerts

  • Ratios and Analysis

    How does this fund compare against other funds in Biotechnology & Healthcare?

    Quartile Ranking

        1y 3y
    ? Position 2 / 4 3 / 4
    ? Quartile 2 3

    Ranking is for the main unit within the sector View other funds in this sector

    Other Rating

    Morningstar Analyst

    Ratio Info

        1y 3y
    ? Volatility 21.24 28.08
    ? Alpha -3.20 -7.83
    ? Beta 1.51 1.34
    ? Sharpe 0.58 0.35
    ? Info Ratio 0.15 -0.30
    ? R2 0.65 0.86
    ? Quartiles:1 2 3 4

    Risk Score

    FE Risk scores allow you to see how risky a fund is in comparison with the FTSE 100.

    This fund: 222
    FTSE 100: 100
    Cash: 0

    Investment Details

    Initial n/a
    Annual 0.65%
    ? OCF 1.10%
    ? Performance Fee N/A
    Minimum Investment?
    Initial n/a
    Additional n/a
  • Prices and Codes


                Diluted NAV   Div yield
      Currency Bid Offer Date Prem/Disc Estimated Last Published Gearing Net Gross
    The Biotech Growth Trust PLC GBX 870.00 19 Oct 2017 -4.13 907.50 907.50 109 0.00 0.00


      Unit type Exchange TIDM Citicode SEDOL ISIN
    The Biotech Growth Trust PLC INC BIOG AKR0 0038551 GB0000385517
  • What does this fund invest in?

    Asset Class Breakdown (31 Aug 2017)

    Rank Asset %    
    1 North American Equities 91.30
    2 European Equities 5.50
    3 International Equities 1.60
    4 UK Equities 1.60

    Top Holdings (31 Aug 2017)

    Rank Largest Holdings %  
    1 Biogen 12.60
    2 Celgene 11.80
    3 Vertex Pharmaceuticals 9.30
    4 Regeneron Pharmaceuticals 7.10
    5 Alexion Pharmaceuticals 6.20
    6 Incyte 5.80
    7 Amgen 5.30
    8 Gilead Sciences 4.20
    9 Illumina 4.00
    10 DBV Technologies 3.10
  • Additional Information

    Additional Information

    Legal Structure: INVT
    Nominal value: N/A
    Fund Launch: 23-Jun-1997
    Unit Launch: 23-Jun-1997
    Savings plan: NO
    Last AGM: 12-Jul-2016
    Stockbroker(s): Winterflood Investment Trusts
    Wind-up date: N/A
    Dividend policy: N/A
    Settlement Details: N/A
    Issued: 55,840
    Asset Class: Equity
    Annual accounts: annual accounts Click here to order
    Next AGM: July 2018
    Management Contract: Under a new management, administration and company secr... More
    Continuation/Wind-up provision: As part of the package of measures adopted by the Board... More
    Investment Restrictions: N/A
    Tax Policy: N/A
    Fund Size: £485.8m / $639.4m (19-Oct-17)
    Market Value: £ 485.81m
    Own ISA wrapper: YES help with ISA
    Last report / accounts: 25-May-2017
    EGM: 30-Oct-2013
    Borrowing limits: Borrowing must not exceed 25% of the adjusted capital a... More
    Splits: N/A
    Reconstruction proposal: N/A
    News: company announcements
  • News and Research about this fund

    Relevant articles

    Relevant Guides

  • Contact Details

    Frostrow Capital LLP, 25 Southampton Buildings, London, WC2A 1AL

    0203 043 8889 (Fax Number)
    0203 008 4910 (Main Number)

Annual Management Charges: 0.65% of net assets plus 0.30% of market cap. plus £60,000;

All prices in Pence Sterling (GBX) unless otherwise specified. Price total return performance figures are calculated using closing mid prices and with net income (dividends) reinvested. fair value cum income NAV figures (in accordance with AIC guidelines) and with net income (dividends) reinvested. Performance figures are shown in Pound Sterling (GBP). You can switch the fund’s native currency using the currency selector towards the top of this page.

Your custom layout changed and saved automatically
Drag and drop the icon to customise your factsheet layout
Data provided by FE. Care has been taken to ensure that the information is correct, but FE neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close